Detalhe da pesquisa
1.
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
BJU Int
; 103(12): 1641-6, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19210673
2.
Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.
Drugs Aging
; 24(10): 865-79, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17896834
3.
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
J Clin Oncol
; 23(15): 3343-51, 2005 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15738542
4.
Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.
Eur Urol
; 56(3): 479-84, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18585841
5.
Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot.
Cancer
; 112(7): 1625-31, 2008 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18286527
6.
Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
Prostate
; 67(14): 1543-9, 2007 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17705243
7.
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
J Urol
; 177(5): 1698-702, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17437788